

Welcome to STN International! Enter x:X

LOGINID:SSPTASMR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS	3	NOV 26	MARPAT enhanced with FSORT command
NEWS	4	NOV 26	CHEMSAFE now available on STN Easy
NEWS	5	NOV 26	Two new SET commands increase convenience of STN searching
NEWS	6	DEC 01	ChemPort single article sales feature unavailable
NEWS	7	DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS	8	DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS	9	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS	10	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS	11	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS	12	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS	13	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS	14	FEB 10	COMPENDEX reloaded and enhanced
NEWS	15	FEB 11	WTEXTILES reloaded and enhanced
NEWS	16	FEB 19	New patent-examiner citations in 300,000 CA/CAPLUS patent records provide insights into related prior art
NEWS	17	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS	18	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS	19	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS	20	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS	21	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS	22	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS	23	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS EXPRESS	JUNE 27 08	CURRENT WINDOWS VERSION IS V8.3,	
		AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.	
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 13:48:53 ON 09 MAR 2009

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.44	0.44

FILE 'REGISTRY' ENTERED AT 13:50:06 ON 09 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 6 MAR 2009 HIGHEST RN 1116745-20-0
DICTIONARY FILE UPDATES: 6 MAR 2009 HIGHEST RN 1116745-20-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>
Uploading C:\Program Files\STNEXP\Queries\10588235 str 2.str

L1 STRUCTURE UPLOADED

=> s l1 sss full
FULL SEARCH INITIATED 13:50:30 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 262 TO ITERATE

100.0% PROCESSED	262 ITERATIONS	73 ANSWERS
SEARCH TIME: 00.00.01		

L2 73 SEA SSS FUL L1

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	185.88	186.32

FILE 'CAPLUS' ENTERED AT 13:50:46 ON 09 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Mar 2009 VOL 150 ISS 11
FILE LAST UPDATED: 8 Mar 2009 (20090308/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l2 ibib ab hitstr
MISSING OPERATOR L2 IBIB
The search profile that was entered contains terms or nested terms that are not separated by a logical operator.

=> s l2
L3 7 L2

=> d l3 1-7 ibib ab hitstr

L3 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2007:281174 CAPLUS
DOCUMENT NUMBER: 146:330828
TITLE: Pharmaceutical compositions containing α -4
integrin mediated cell adhesion inhibitors
INVENTOR(S): Ward, Robert William; Witherington, Jason
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 38pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2007063268	A	20070315	JP 2006-212923	20060804
PRIORITY APPLN. INFO.:			JP 2005-227980	A 20050805
OTHER SOURCE(S):	MARPAT	146:330828		
AB The invention relates to a pharmaceutical composition characterized by containing a				

compound I [A, B, D = aryl, heteroaryl; R1, R2, R3 = C1-6 alkyl, halogen, C1-6 alkoxy, hydroxy, cyano, CF3, OCF3, nitro, C1-6 alkylthio, amino, mono-(di)-C1-6 alkylamino, carboxy, C1-6 alkanoyl, amido, mono-(di)-C1-6 alkylamido, etc; R4, R4' = H, C1-6 alkyl, halogen, C1-6 alkoxy; V = O, S, NH, N-C1-6 alkyl, NNO2, NCN; W, X, Y, Z = C, CH, N, wherein at least one of X, Y, and Z is N; L = -(CH2)q-, -(CH2)q'O-, wherein q = 0-3, q' = 2, 3; J = -CR5:CR6-, wherein R5, R6 = H, C1-6 alkyl, single bond, etc.; m, n, p = 0-3; t = 0-2], or its pharmaceutically acceptable derivative as an active component. The compound has an inhibitory effect against α -4 integrin mediated cell adhesion, and is suitable for use for treatment of α -4 integrin mediated cell adhesion-related disease, e.g. asthma, enteritis, rheumatic arthritis, and multiple sclerosis, etc. For example, a compound (R,S)-3-[4-[5-[3-ethoxy-4-(3-o-tolylureido)phenyl]-6-oxo-6H-pyrimidin-1-ylmethyl]phenyl]butyric acid was prepared, and examined for its interaction with integrin VLA-4 in vitro.


IT 862855-36-5P 862855-37-6P 862855-38-7P
862855-39-8P 862855-42-3P 862855-43-4P
862855-44-5P 862855-45-6P 862855-47-8P
862855-48-9P 862855-49-0P 862855-50-3P
862855-51-4P 862855-52-5P 862855-53-6P
862855-54-7P 928080-46-0P 928080-53-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pharmaceutical compns. containing α -4 integrin mediated cell adhesion inhibitors)

RN 862855-36-5 CAPLUS

CN Benzenepropanoic acid, β -methyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]-, (BR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-37-6 CAPLUS


CN Benzenepropanoic acid, β -ethyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]-, (BR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862855-38-7 CAPLUS


CN Benzenepropanoic acid, 4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]- (CA INDEX NAME)



RN 862855-39-8 CAPLUS

CN Benzenepropanoic acid, β -methyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-, (β R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-42-3 CAPLUS


CN Benzenepropanoic acid, 4-[[5-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]- β -methyl-, (β R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862855-43-4 CAPLUS
 CN Benzenepropanoic acid, 4-[[5-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-β-methyl-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862855-44-5 CAPLUS
 CN Benzenepropanoic acid, 4-[[5-[3-ethoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-β-methyl-, (CA INDEX NAME)



RN 862855-45-6 CAPLUS
 CN Benzenepropanoic acid, β-methyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyridazinyl]methyl]-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-47-8 CAPLUS

CN Benzenepropanoic acid, β -ethyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyridazinyl]methyl]-, (PS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-48-9 CAPLUS

CN Benzenepropanoic acid, 4-[[5-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyridazinyl]methyl]-, β -methyl-, (BR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-49-0 CAPLUS


CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]-, β -methyl-, (BR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862855-50-3 CAPLUS


CN Benzenepropanoic acid, 4-[[[2,4-dimethyl-5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-β-methyl]- (CA INDEX NAME)



RN 862855-51-4 CAPLUS

CN Benzenepropanoic acid, 4-[[[2,4-dimethyl-5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-β-methyl]-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-52-5 CAPLUS

CN Benzenepropanoic acid, 4-[[[2,4-dimethyl-5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-β-methyl]-, (βS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-53-6 CAPLUS

CN Benzenepropanoic acid, 4-[[5-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2,4-dimethyl-6-oxo-1(6H)-pyrimidinyl]methyl]-β-methyl-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-54-7 CAPLUS

CN Benzenepropanoic acid, β-ethyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyridazinyl]methyl]-, sodium salt (1:1), (βR)- (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 928080-46-0 CAPLUS

CN Benzenepropanoic acid, β-ethyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-, sodium salt (1:1), (βR)- (CA INDEX NAME)

, sodium salt (1:1), (BR)- (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 928080-53-9 CAPLUS

CN Benzenepropanoic acid, β -ethyl-4-[[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-, sodium salt (1:1), (BS)- (CA INDEX NAME)

Absolute stereochemistry.



● Na

IT 862855-64-9P 862855-78-5P 862855-91-2P


862855-96-7P 928082-53-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pharmaceutical compns. containing α -4 integrin mediated cell adhesion inhibitors)

RN 862855-64-9 CAPLUS


CN Benzenepropanoic acid, 4-[[[5-[3-ethoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]- β -methyl-, ethyl ester (CA INDEX NAME)



RN 862855-78-5 CAPLUS

CN Benzenepropanoic acid, β -ethyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyridazinyl]methyl]-, methyl ester, (BR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-91-2 CAPLUS

CN Benzenepropanoic acid, 4-[[2,4-dimethyl-5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]- β -methyl-, methyl ester, (BR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-96-7 CAPLUS


CN Benzenepropanoic acid, 4-[[5-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2,4-dimethyl-6-oxo-1(6H)-pyrimidinyl]methyl]- β -methyl-, methyl ester, (BR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 928082-53-5 CAPLUS
 CN Benzenepropanoic acid, β-methyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-, methyl ester, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



L3 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:100119 CAPLUS
 DOCUMENT NUMBER: 146:213
 TITLE: Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists
 AUTHOR(S): Witherington, Jason; Blaney, Emma L.; Bordas, Vincent; Elliott, Richard L.; Gaiba, Alessandra; Garton, Neil; Green, Philip M.; Naylor, Antoinette; Smith, David G.; Spalding, David J.; Takle, Andrew K.; Ward, Robert W.
 CORPORATE SOURCE: Department of DMPK and Medicinal Chemistry, Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research Limited, Essex, CM19 5AW, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(21), 5538-5541
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 146:213
 AB A series of pyridone-N-benzylpropanoic acids have been optimized to afford potent orally bioavailable VLA-4 antagonists.
 IT 915157-69-6 915157-73-2 915157-74-3
 915157-75-4 915157-76-5
 RL: PAC (Pharmacological activity); BIOL (Biological study)
 (optimization of pyridone-N-benzylpropanoic acids as orally bioavailable VLA-4 integrin antagonists)


RN 915157-69-6 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[2-(1-methylethyl)phenyl]amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)




RN 915157-73-2 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[4-[[[(2,3-dimethylphenyl)amino]carbonyl]amino]-3-methoxyphenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)




RN 915157-74-3 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[4-[[[(2,4-dimethylphenyl)amino]carbonyl]amino]-3-methoxyphenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)




RN 915157-75-4 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[4-[[[(2,5-dimethylphenyl)amino]carbonyl]amino]-3-methoxyphenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)



RN 915157-76-5 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[4-[[[2,6-dimethylphenyl]amino]carbonyl]amino]-3-methoxyphenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)




IT 660439-96-3

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); BIOL (Biological study)
(optimization of pyridone-N-benzylpropanoic acids as orally bioavailable VLA-4 integrin antagonists)

RN 660439-96-3 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-
(CA INDEX NAME)



IT 660439-93-0P 660440-22-2P 660440-23-3P


915157-77-6P 915157-78-7P 915157-79-8P
915157-80-1P 915157-81-2P 915157-82-3P
915157-83-4P 915157-84-5P 915157-85-6P
915157-86-7P 915157-87-8P 915157-88-9P
915157-89-0P 915157-90-3P 915157-91-4P
915157-93-6P

RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(optimization of pyridone-N-benzylpropanoic acids as orally bioavailable VLA-4 integrin antagonists)

RN 660439-93-0 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[4-[[[2-


methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl)methyl]-
(CA INDEX NAME)



RN 660440-22-2 CAPLUS

CN Benzenepropanoic acid, β -methyl-4-[[[3-(4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl)methyl]-, (PS)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 660440-23-3 CAPLUS

CN Benzenepropanoic acid, β -methyl-4-[[[3-(4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl)methyl]-, (BR)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 915157-77-6 CAPLUS


CN Benzenepropanoic acid, 4-[[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl)methyl]-, (PS)- (CA INDEX NAME)

Absolute stereochemistry.




RN 915157-78-7 CAPLUS
 CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-β-methyl-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 915157-79-8 CAPLUS
 CN Benzenepropanoic acid, 4-[[3-[3-chloro-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-β-methyl-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 915157-80-1 CAPLUS
 CN Benzenepropanoic acid, β-methyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]-3-(trifluoromethoxy)phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (βR)- (CA INDEX NAME)

methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl)methyl]-,
(BR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 915157-84-5 CAPLUS

CN Benzenepropanoic acid, 4-[[[3-(2-chloro-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl)methyl]-β-methyl]-, (BR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 915157-85-6 CAPLUS

CN Benzenepropanoic acid, β-methyl-4-[[[3-(2-methyl-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl)methyl]-, (BR)- (CA INDEX NAME)

Absolute stereochemistry.




RN 915157-86-7 CAPLUS

CN Benzenepropanoic acid, 4-[[[3-(3-chloro-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl)methyl]-, (BR)- (CA INDEX NAME)

methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl)methyl]-
 β -methyl-, (β S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 915157-87-8 CAPLUS

CN Benzenepropanoic acid, β -methyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl)methyl]-, (β S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 915157-88-9 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[3-ethoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl)methyl]-, (β S)- (CA INDEX NAME)

Absolute stereochemistry.



CN Benzenepropanoic acid, 4-[[[3-[3-ethyl-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-β-methyl-, (BS)- (CA INDEX NAME)

CC(=O)Nc1ccc(NC(=O)Nc2ccc(NC(=O)c3ccc(CN(CCC(=O)O)C)cc3)cc2)cc1

CN Benzenepropionic acid, β -methyl-4-[[[3-[3-methyl-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (BS)- (CA INDEX NAME)


CC(=O)Nc1ccc(NC(=O)c2ccc(NC(=O)Cc3ccc(cc3)C(S)C(=O)O)cc2)cc1

CN Benzenepropanoic acid, 4-[[[3-[2-chloro-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-β-methyl-, (BS)- (CA INDEX NAME)

CC1=CC=C(C=C1)NC(=O)Nc2ccc(cc2Cl)c3c(=O)n(Cc4ccc(cc4)C(S)(C)CC(=O)O)c5ccc(cc35)c6ccccc6


RN 915157-93-6 CAPLUS
CN Benzenepropanoic acid, β -methyl-4-[[3-[2-methyl-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (β S)- (CA INDEX NAME)

Absolute stereochemistry.



IT 926010-03-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(optimization of pyridone-N-benzylpropanoic acids as orally bioavailable VLA-4 integrin antagonists)
RN 926010-03-9 CAPLUS
CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- β -methyl-, methyl ester, (β R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:453930 CAPLUS
DOCUMENT NUMBER: 144:480470
TITLE: Pyridone derivatives as potent and selective VLA-4 integrin antagonists. [Erratum to document cited in CA144:403837]
AUTHOR(S): Witherington, Jason; Bordas, Vincent; Gaiba, Alessandra; Green, Phil M.; Naylor, Antoinette; Parr, Nigel; Smith, David G.; Takle, Andrew K.; Ward, Robert W.
CORPORATE SOURCE: Department of Medicinal Chemistry, Neurology & GI Centre of Excellence for Drug Discovery,


GlaxoSmithKline Research Limited Harlow, Essex, CM19 5AW, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006), 16(12), 3341
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB The legends to Figures 1b and 3b are incorrect. In Figure 1b, the legend should read: "GASP molecular overlay of 8 (green) and 5 (yellow)". In Figure 3b, the legend should read: "Molecular overlay of 8 (green) and 10 (yellow)".

IT 660439-93-0P 660439-96-3P 660439-99-6P
 884348-00-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (pyridone derivs. as potent and selective VLA-4 integrin antagonists (Erratum))


RN 660439-93-0 CAPLUS

CN Benzenepropanoic acid, 4-[[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)




RN 660439-96-3 CAPLUS

CN Benzenepropanoic acid, 4-[[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)




RN 660439-99-6 CAPLUS


CN Benzoic acid, 4-[[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)



RN 884348-00-9 CAPLUS
 CN Benzenecetic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-
 (CA INDEX NAME)



IT 660440-04-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (pyridone derivs. as potent and selective VLA-4 integrin antagonists
 (Erratum))
 RN 660440-04-0 CAPLUS
 CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-,
 methyl ester (CA INDEX NAME)



L3 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2006:232883 CAPLUS
 DOCUMENT NUMBER: 144:403837
 TITLE: Pyridone derivatives as potent and selective VLA-4
 integrin antagonists
 AUTHOR(S): Witherington, Jason; Bordas, Vincent; Gaiba,
 Alessandra; Green, Phil M.; Naylor, Antoinette; Parr,
 Nigel; Smith, David G.; Takle, Andrew K.; Ward, Robert
 W.
 CORPORATE SOURCE: Department of Medicinal Chemistry, Neurology & GI
 Centre of Excellence for Drug Discovery,
 GlaxoSmithKline Research Limited, Essex, CM19 5AW, UK
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2006),

16(8), 2256-2259

CODEN: BMCLE8; ISSN: 0960-894X

Elsevier B.V.

PUBLISHER:

DOCUMENT TYPE:

Journal

LANGUAGE:

English

OTHER SOURCE(S):

CASREACT 144:403837

AB A novel series of pyridone inhibitors has been identified through pharmacophore anal., as potent antagonists of VLA-4. Analog I exhibited excellent inhibitory potency.

IT 660439-93-0P 660439-96-3P 660439-99-6P


884348-00-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(pyridone derivs. as potent and selective VLA-4 integrin antagonists)


RN 660439-93-0 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)




RN 660439-96-3 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)




RN 660439-99-6 CAPLUS


CN Benzoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)



RN 884348-00-9 CAPLUS
 CN Benzenecetic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-
 (CA INDEX NAME)



IT 660440-04-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (pyridone derivs. as potent and selective VLA-4 integrin antagonists)
 RN 660440-04-0 CAPLUS
 CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-,
 methyl ester (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on SIN
 ACCESSION NUMBER: 2005:1025806 CAPLUS
 DOCUMENT NUMBER: 143:299147
 TITLE: Medicine compositions containing pyridone analogs for
 inhibiting α 4-integrin-mediated cell adhesion
 INVENTOR(S): Witherington, Jason; Elliott, Richard Leonard
 PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 36 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005255675	A	20050922	JP 2005-33237	20050209
PRIORITY APPLN. INFO.: OTHER SOURCE(S):			JP 2004-31901	A 20040209

AB Medicine comps. containing pyridone analogs and their pharmacol. acceptable
 salts are claimed for inhibiting α 4-integrin-mediated cell adhesion
 for treatment of related diseases, including chronic inflammatory

diseases, asthma, allergy, inflammatory bowel disease, rheumatoid arthritis, atopic dermatitis, multiple sclerosis, organ transplant rejection, cardiovascular disease, diabetes, tumor, central nervous system diseases, etc.


IT 660439-93-0P 660439-96-3P 660439-98-5P
660439-99-6P 660440-00-6P 660440-03-9P
660440-04-0P 660440-06-2P 660440-08-4P
660440-09-5P 660440-10-8P 660440-11-9P
660440-14-2P 660440-20-0P 660440-21-1P
660440-22-2P 660440-23-3P 660440-24-4P
660440-25-5P 660440-26-6P 660440-27-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(medicine compns. containing pyridone analogs for inhibiting $\alpha 4$ -integrin-mediated cell adhesion and treating related diseases)


RN 660439-93-0 CAPLUS

CN Benzenepropanoic acid, 4-[[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-(CA INDEX NAME)




RN 660439-96-3 CAPLUS

CN Benzenepropanoic acid, 4-[[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-(CA INDEX NAME)




RN 660439-98-5 CAPLUS

CN Benzenepropanoic acid, 4-[[[5-chloro-3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-(CA INDEX NAME)




RN 660439-99-6 CAPLUS

CN Benzoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)




RN 660440-00-6 CAPLUS

CN Benzenepropanoic acid, beta-methyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)




RN 660440-03-9 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-beta-methyl- (CA INDEX NAME)




RN 660440-04-0 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 660440-06-2 CAPLUS
 CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, ethyl ester (CA INDEX NAME)




RN 660440-08-4 CAPLUS
 CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, [[(cyclohexyloxy)carbonyl]oxy]methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 660440-09-5 CAPLUS
 CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, [[(1-methylethoxy)carbonyl]oxy]methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B



RN 660440-10-8 CAPLUS
CN Benzenepropanoic acid, 4-[[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (acetyloxy)methyl ester (CA INDEX NAME)


PAGE 1-A



PAGE 1-B




RN 660440-11-9 CAPLUS
CN Benzenepropanoic acid, 4-[[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, 1-methylethyl ester (CA INDEX NAME)




RN 660440-14-2 CAPLUS

CN Phenylalanine, N-acetyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)




RN 660440-20-0 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[4-[[[(3-fluoro-2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)



RN 660440-21-1 CAPLUS


CN Benzenepropanoic acid, 4-[[3-[2-fluoro-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)



RN 660440-22-2 CAPLUS

CN Benzenepropanoic acid, β-methyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (βS)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 660440-23-3 CAPLUS


CN Benzenepropanoic acid, β -methyl-4-[[3-[4-[[[2-(methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (BR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 660440-24-4 CAPLUS


CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-β-phenyl- (CA INDEX NAME)



RN 660440-25-5 CAPLUS

CN Benzenepropanoic acid, β -ethyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (BS)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 660440-26-6 CAPLUS


CN Benzenepropanoic acid, β -ethyl-4-[[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (BR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 660440-27-7 CAPLUS

CN Benzenepropanoic acid, β,β -dimethyl-4-[[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (CA INDEX NAME)




IT 660440-58-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(medicine compns. containing pyridone analogs for inhibiting $\alpha 4$ -integrin-mediated cell adhesion and treating related diseases)

RN 660440-58-4 CAPLUS

CN Benzenepropanoic acid, β -methyl-4-[[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, methyl ester (CA INDEX NAME)



L3 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:823674 CAPLUS

DOCUMENT NUMBER: 143:229873

TITLE: Preparation of 2-(phenylmethyl)pyrimidinones and related compounds as alpha-4 integrin mediated cell adhesion inhibitors for the treatment of inflammatory diseases

INVENTOR(S): Ward, Robert William; Witherington, Jason

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005075438	A1	20050818	WO 2005-JP2194	20050208
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2554705	A1	20050818	CA 2005-2554705	20050208
EP 1737826	A1	20070103	EP 2005-710195	20050208
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR			
CN 1918133	A	20070221	CN 2005-80004473	20050208
JP 2007522146	T	20070809	JP 2006-552027	20050208
US 20080234301	A1	20080925	US 2006-588235	20060803
PRIORITY APPLN. INFO.:			GB 2004-2812	A 20040209
			WO 2005-JP2194	W 20050208
OTHER SOURCE(S):	CASREACT 143:229873; MARPAT 143:229873			
AB	Title comds. I [R1' = (R1)m; R2' = (R2)n; D = (CH2)t; R3' = (R3)p; R1, R2, R3 = alkyl, halo, alkoxy, etc.; R4, R4' = H, alkyl, halo, etc.; V = O, S, NH, etc.; W, X, Y, Z = C, CH, N, subject to the proviso that at least one X Y and Z is N; L = (CH2)q, (CH2)q'O; J = bond, CR5=CR6, CHR7CHR8, etc.; R5, R6 = H, alkyl; R7, R8 = H, alkyl, cycloalkyl, etc.; q = 0-3; q' = 2,3; A, B, D = aryl, heteroaryl; m, n, p = 0-3; t = 0-2] and their pharmaceutically acceptable salts were prepared For example, saponification of Et ester II (G = OEt) afforded carboxylic acid II (G = OH). Compounds I are claimed to be useful as alpha-4 integrin mediated cell adhesion inhibitors			

(no data provided).

IT 862855-36-5P 862855-37-6P 862855-38-7P
862855-39-8P 862855-40-1P 862855-41-2P
862855-42-3P 862855-43-4P 862855-44-5P
862855-45-6P 862855-46-7P 862855-47-8P
862855-48-9P 862855-49-0P 862855-50-3P
862855-51-4P 862855-52-5P 862855-53-6P
862855-54-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 2-(phenylmethyl)pyrimidinones and related compds. as alpha-4
integrin mediated cell adhesion inhibitors for the treatment of
inflammatory diseases)

RN 862855-36-5 CAPLUS

CN Benzenepropanoic acid, beta-methyl-4-[[3-[4-[[[(2-
methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]-,
(BR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-37-6 CAPLUS


CN Benzenepropanoic acid, beta-ethyl-4-[[3-[4-[[[(2-
methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]-,
(BR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862855-38-7 CAPLUS


CN Benzenepropanoic acid, 4-[[5-[4-[[[(2-
methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-
(CA INDEX NAME)



RN 862855-39-8 CAPLUS

CN Benzenepropanoic acid, β -methyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-, (BR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-40-1 CAPLUS

CN Benzenepropanoic acid, β -ethyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-, (BR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-41-2 CAPLUS

CN Benzenepropanoic acid, β -ethyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-, (BS)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-42-3 CAPLUS

CN Benzenepropanoic acid, 4-[[5-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-β-methyl-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-43-4 CAPLUS


CN Benzenepropanoic acid, 4-[[5-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-β-methyl-, (βS)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862855-44-5 CAPLUS


CN Benzenepropanoic acid, 4-[[5-[3-ethoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-β-methyl- (CA INDEX NAME)



RN 862855-45-6 CAPLUS

CN Benzenepropanoic acid, β -methyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyridazinyl]methyl]-, (β R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-46-7 CAPLUS

CN Benzenepropanoic acid, β -ethyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyridazinyl]methyl]-, (β R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-47-8 CAPLUS

CN Benzenepropanoic acid, β -ethyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyridazinyl]methyl]-, (β S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-48-9 CAPLUS

CN Benzenepropanoic acid, 4-[[5-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyridazinyl]methyl]-β-methyl-, (βR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-49-0 CAPLUS


CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyrazinyl]methyl]-β-methyl-, (βR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 862855-50-3 CAPLUS


CN Benzenepropanoic acid, 4-[[2,4-dimethyl-5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-β-methyl- (CA INDEX NAME)



RN 862855-51-4 CAPLUS

CN Benzenepropanoic acid, 4-[[[2,4-dimethyl-5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-β-methyl-, (R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-52-5 CAPLUS

CN Benzenepropanoic acid, 4-[[[2,4-dimethyl-5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-β-methyl-, (S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-53-6 CAPLUS


CN Benzenepropanoic acid, 4-[[[5-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2,4-dimethyl-6-oxo-1(6H)-pyrimidinyl]methyl]-β-methyl-, (R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 862855-54-7 CAPLUS
 CN Benzenepropanoic acid, β -ethyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyridazinyl]methyl]-, sodium salt (1:1), (BR)- (CA INDEX NAME)

Absolute stereochemistry.



● Na


IT 862855-64-9P 862855-78-5P 862855-91-2P, Methyl
 (3R)-3-[4-[[[2,4-dimethyl-5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]phenyl]butanoate 862855-96-7P
 928082-53-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 2-(phenylmethyl)pyrimidinones and related compds. as α -4 integrin mediated cell adhesion inhibitors for the treatment of inflammatory diseases)
 RN 862855-64-9 CAPLUS
 CN Benzenepropanoic acid, 4-[[5-[3-ethoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]- β -methyl-, ethyl ester (CA INDEX NAME)



RN 862855-78-5 CAPLUS

CN Benzenepropanoic acid, β -ethyl-4-[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyridazinyl]methyl]-, methyl ester, (BR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-91-2 CAPLUS

CN Benzenepropanoic acid, 4-[[2,4-dimethyl-5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]- β -methyl-, methyl ester, (BR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 862855-96-7 CAPLUS


CN Benzenepropanoic acid, 4-[[5-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2,4-dimethyl-6-oxo-1(6H)-pyrimidinyl]methyl]- β -methyl-, methyl ester, (BR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 928082-53-5 CAPLUS
 CN Benzenepropanoic acid, β -methyl-4-[[[5-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-6-oxo-1(6H)-pyrimidinyl]methyl]-, methyl ester, (β R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on SIN
 ACCESSION NUMBER: 2004:143107 CAPLUS
 DOCUMENT NUMBER: 140:199207
 TITLE: Preparation of pyridones as inhibitors of α 4 integrin-mediated cell adhesion.
 Witherington, Jason; Elliott, Richard Leonard
 INVENTOR(S): Tanabe Seiyaku Co., Ltd., Japan
 PATENT ASSIGNEE(S): PCI Int. Appl., 47 pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004014859	A2	20040219	WO 2003-JP10119	20030808
WO 2004014859	A3	20040415		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2493660 A1 20040219 CA 2003-2493660 20030808
 AU 2003256069 A1 20040225 AU 2003-256069 20030808
 EP 1539696 A2 20050615 EP 2003-784602 20030808

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

CN 1688548 A 20051026 CN 2003-823831 20030808
 JP 2005535702 T 20051124 JP 2004-527373 20030808
 US 20050288337 A1 20051229 US 2005-524028 20050209
 US 7410984 B2 20080812

PRIORITY APPLN. INFO.: GB 2002-18630 A 20020810
 WO 2003-JP10119 W 20030808


OTHER SOURCE(S): MARPAT 140:199207

AB Title compds. [I; A, B = aryl, heteroaryl; Q = C, CH; QV, QD = 5-7 membered heterocyclyl; D = H, alkyl; R1-R3 = alkyl, halo, alkoxy, OH, cyano, CF3, NO2, alkylthio, amino, CO2H, alkanoyl, amido, NHCOR9, NHSO2R9; R9 = alkyl, cycloalkyl, (substituted) Ph etc.; R4 = H, alkyl, halo, alkoxy; V = O, S, amino, NNO2, NCN; W, X, Y, Z = C, CH, CH2; dotted line = single or double bond; L = (CH2)r, (CH2)rrO; r = 0-3; rr = 2, 3; J = CR5; CR6, CHR7/CHR8, single bond, CHR6; OCHR10, etc.; R5, R6, R10 = H, alkyl; R7, R8 = H, alkyl, cycloalkyl, aryl, heteroaryl, etc.; m, n, p = 0-3; q = 0-2], were prepared as inhibitors of α 4 integrin-mediated cell adhesion (no data). Thus, Et 3-[4-[2-oxo-3-[4-(3-o-tolylureido)phenyl]-2H-pyridin-1-ylmethyl]phenyl]propionate and LiOH were stirred at 60° for 30 min in THF/H2O to give after acidification with HCl 3-[3-[2-oxo-3-[4-(3-o-tolylureido)phenyl]-2H-pyridin-1-ylmethyl]phenyl]propionic acid.

IT 660440-06-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of pyridones as inhibitors of α 4 integrin-mediated cell adhesion)

RN 660440-06-2 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, ethyl ester (CA INDEX NAME)



IT 660439-93-0P 660439-96-3P 660439-98-5P
 660439-99-6P 660440-00-6P 660440-03-9P
 660440-04-0P 660440-08-4P 660440-09-5P
 660440-10-8P 660440-11-9P 660440-14-2P
 660440-20-0P 660440-21-1P 660440-22-2P
 660440-23-3P 660440-24-4P 660440-25-5P
 660440-26-6P 660440-27-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyridones as inhibitors of $\alpha 4$ integrin-mediated cell adhesion)


RN 660439-93-0 CAPLUS

CN Benzenepropanoic acid, 4-[[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-(CA INDEX NAME)




RN 660439-96-3 CAPLUS

CN Benzenepropanoic acid, 4-[[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-(CA INDEX NAME)




RN 660439-98-5 CAPLUS

CN Benzenepropanoic acid, 4-[[[5-chloro-3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-(CA INDEX NAME)




RN 660439-99-6 CAPLUS

CN Benzoic acid, 4-[[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-(CA INDEX NAME)




RN 660440-00-6 CAPLUS

CN Benzenepropanoic acid, β-methyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)




RN 660440-03-9 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[3-methoxy-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-β-methyl- (CA INDEX NAME)



RN 660440-04-0 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, methyl ester (CA INDEX NAME)




RN 660440-08-4 CAPLUS


CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, methyl ester (CA INDEX NAME)

[[cyclohexyloxy]carbonyloxy]methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 660440-09-5 CAPLUS

CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, [[(1-methylethoxy)carbonyloxy]methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 660440-10-8 CAPLUS


CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (acetyloxy)methyl ester (CA INDEX NAME)




RN 660440-11-9 CAPLUS
 CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-1-methylethyl ester (CA INDEX NAME)



RN 660440-14-2 CAPLUS
 CN Phenylalanine, N-acetyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-1-methylethyl ester (CA INDEX NAME)




RN 660440-20-0 CAPLUS
 CN Benzenepropanoic acid, 4-[[3-[4-[[[(3-fluoro-2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-1-methylethyl ester (CA INDEX NAME)



RN 660440-21-1 CAPLUS


CN Benzenepropanoic acid, 4-[[3-[2-fluoro-4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)



RN 660440-22-2 CAPLUS

CN Benzenepropanoic acid, β -methyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (PS)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 660440-23-3 CAPLUS


CN Benzenepropanoic acid, β -methyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (BR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 660440-24-4 CAPLUS


CN Benzenepropanoic acid, 4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- β -phenyl- (CA INDEX NAME)



RN 660440-25-5 CAPLUS

CN Benzenepropanoic acid, β -ethyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (BS)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 660440-26-6 CAPLUS


CN Benzenepropanoic acid, β -ethyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, (BR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 660440-27-7 CAPLUS

CN Benzenepropanoic acid, β,β -dimethyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]- (CA INDEX NAME)




IT 660440-58-4

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyridones as inhibitors of $\alpha 4$ integrin-mediated cell adhesion)

RN 660440-58-4 CAPLUS

CN Benzenepropanoic acid, β -methyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, methyl ester (CA INDEX NAME)




IT 660440-49-3P 660440-50-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridones as inhibitors of $\alpha 4$ integrin-mediated cell adhesion)

RN 660440-49-3 CAPLUS

CN Benzenepropanoic acid, β -methyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, methyl ester, (BR)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 660440-50-6 CAPLUS

CN Benzenepropanoic acid, β -methyl-4-[[3-[4-[[[(2-methylphenyl)amino]carbonyl]amino]phenyl]-2-oxo-1(2H)-pyridinyl]methyl]-, methyl ester, (BS)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

